IL-6 inhibition in critically ill COVID-19 patients is associated with increased secondary infections

Lucas M. Kimmig, David Wu, Matthew Gold, Natasha N Pettit, David Pitrak, Jeffery Mueller, Aliya N. Husain, Ece A. Mutlu, Gökhan M. Mutlu
doi: https://doi.org/10.1101/2020.05.15.20103531

Article usage

Article usage: May 2020 to October 2024

AbstractFullPdf
May 2020658702136
Jun 202012790430
Jul 202017770452
Aug 20207960230
Sep 20208110339
Oct 20205370255
Nov 20203400143
Dec 20201840106
Jan 20212811139
Feb 20211990123
Mar 202121216108
Apr 20212006149
May 20212086180
Jun 2021131599
Jul 20211146103
Aug 20211001883
Sep 2021100367
Oct 2021122486
Nov 2021117379
Dec 2021122254
Jan 202298873
Feb 202289347
Mar 2022105048
Apr 2022115852
May 202274144
Jun 202293338
Jul 202275232
Aug 202292434
Sep 202285442
Oct 202261032
Nov 202268134
Dec 202287230
Jan 202379124
Feb 202393642
Mar 202352227
Apr 202372227
May 202365141
Jun 202350428
Jul 202364126
Aug 2023781336
Sep 202373532
Oct 2023209130
Nov 20232261222
Dec 202330026
Jan 202423123
Feb 202438222
Mar 2024361027
Apr 2024401220
May 202424424
Jun 202426822
Jul 202441225
Aug 202448829
Sep 202446224
Oct 202435523
Back to top
Posted September 12, 2020.
Download PDF
Data/Code
Email
IL-6 inhibition in critically ill COVID-19 patients is associated with increased secondary infections
Lucas M. Kimmig, David Wu, Matthew Gold, Natasha N Pettit, David Pitrak, Jeffery Mueller, Aliya N. Husain, Ece A. Mutlu, Gökhan M. Mutlu
medRxiv 2020.05.15.20103531; doi: https://doi.org/10.1101/2020.05.15.20103531
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area